CLEVELAND — The advance of digital technology has changed the way the health care industry thinks about innovation. A decade ago the most talked about innovations at the Cleveland Clinic's Medical Innovation Summit were traditional devices and pharmaceuticals. At this year's summit, which concluded Wednesday, digital health companies stole the show. But that doesn't mean the traditional device makers were left out of the conversation.
Abbott Laboratories and St. Jude Medical Inc. have kept analysts' busy this week, sifting through both companies' third quarter financials, looking for the read-through of Tuesday's $1.12 billion deal with Terumo Corp., trying to make heads or tails of Muddy Waters' latest cybersecurity attacks against St. Jude, all the while getting little clarity about the $5.8 billion elephant in the room otherwise known as Alere Inc. And yet, after nearly eight months of turbulence related to Abbott's pending merger with Alere, one of the most surprising takeaways from Abbott's...
Abbott Laboratories and St. Jude Medical Inc. have kept analysts' busy this week, sifting through both companies' third quarter financials, looking for the read-through of Tuesday's $1.12 billion deal with Terumo Corp., trying to make heads or tails of Muddy Waters' latest cybersecurity attacks against St. Jude, all the while getting little clarity about the $5.8 billion elephant in the room otherwise known as Alere Inc.
A single-port laparoscopic device designed to knock down a key barrier in the space has earned a financial boost just days ahead of the product's official U.S. launch. Chemelot Ventures led Fortimedix Surgical B.V.'s €11 million series A round to support the company's FMX314, which recently won both FDA clearance and a CE mark, and is compatible with a standard-sized trocar that laparoscopic surgeons are most familiar with. Fortimedix, of Nuth, Netherlands, plans to launch the device in the U.S. at the American College of Surgeons Clinical Congress next week in Washington, with a European launch to follow in 2017....
San Diego-based Biocept Inc. has been on a roll this year to carve out a spot for itself in the emerging field of liquid biopsy and personalized medicine. A $10 million offering of common stock and warrants is the company's latest move to support its expanding menu of available companion tests for immuno-oncology therapeutics. The company said Friday it would sell stock (9.1 million shares) and warrants (for 9.1 million shares) at a combined price of $1.10. The warrants will be good for up to five years. The offering, which is expected to close...
